Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology

Daily Management: Inhalers, Vaccines, and Rehabilitation

At a Glance

Daily COPD care combines the right maintenance inhaler, recommended vaccines, correct inhaler technique, smoking cessation, and pulmonary rehabilitation. Together, these steps can ease symptoms, lower flare-up risk, and help you stay active, while your clinician tailors treatment to your needs.

Managing COPD is a daily commitment to protecting your lungs and maintaining your quality of life. While the disease cannot be reversed, a combination of specialized medications, vaccinations, and physical conditioning can significantly reduce your symptoms and keep you out of the hospital [1][2].

The Foundation: Protection and Prevention

Before starting any inhaler, the most effective “treatments” for COPD involve removing irritants and preventing infections that cause lung damage.

  • Smoking Cessation: Stopping smoking is the only intervention proven to slow the long-term decline of lung function [3]. Your doctor can provide pharmacologic support, such as nicotine replacement or prescription medications, to help you succeed.
  • Vaccination: Because a simple virus can trigger a dangerous flare-up, staying up-to-date on vaccines is a “mainstay” of care [3][4]. You should always review your country’s current vaccination schedule with your doctor, as recommendations for Pneumococcal, RSV, COVID-19, Tdap (Pertussis), and Zoster (Shingles) depend on your age, immune status, and prior doses [5][6][7][4][8]. Annual influenza vaccination is universally recommended [9].

Inhaler Therapy

Inhalers are the primary tool for opening your airways. Doctors determine your initial therapy based on your ABE classification, not a one-size-fits-all formula [1][10].

Long-Acting Bronchodilators (LAMA and LABA)

These are your “maintenance” medicines. They work by relaxing the muscles around your airways for 12 to 24 hours.

  • Single Bronchodilator: A LAMA (Long-Acting Muscarinic Antagonist) or LABA (Long-Acting Beta-Agonist) is generally used initially for low-symptom, low-risk patients (Group A).
  • Dual Therapy (LAMA + LABA): Dual LABA/LAMA therapy is commonly preferred initially for patients with substantial symptoms (Group B) or high exacerbation risk (Group E) [11][2]. Reassessment of inhaler adherence, technique, and alternative diagnoses occurs before any therapy escalation.

Inhaled Corticosteroids (ICS)

An Inhaled Corticosteroid (ICS) is a medicine that reduces inflammation. It is generally used to prevent exacerbations in selected patients, or to treat concomitant asthma, not simply for routine breathlessness [10][12].

  • When it is used: Your doctor may consider adding an ICS if you have frequent exacerbations despite dual therapy, or coexisting asthma. The likelihood of benefit is predicted by your blood eosinophil count. Eosinophils operate on a continuum; counts of 300 cells/µL or higher strongly indicate potential benefit, but it is not a rigid cutoff [10][13].
  • The Risks: Using an ICS when you don’t need it exposes you to an increased risk of pneumonia, oral thrush, and a hoarse voice (dysphonia) without clear benefit [14][15][11].

Pulmonary Rehabilitation: Training Your Body

Pulmonary Rehabilitation is a supervised program that combines exercise, education, and support. It is one of the most powerful treatments for improving how far you can walk and how much you enjoy life [16][17].

  • What it does: It doesn’t “fix” your lungs, but it trains your heart and muscles to use oxygen more efficiently, so you don’t feel as winded during daily tasks [18].
  • Timing is key: If you are hospitalized for a flare-up, initiating pulmonary rehabilitation within 3 weeks of discharge is conditionally recommended to help prevent readmissions [19][20].

Success Starts with Technique

Even the best medicine won’t work if it doesn’t reach your lungs. Up to 90% of patients use their inhalers incorrectly at some point [21].

  • Consistency: Maintenance inhalers must be used every day, even when you feel good.
  • Technique: Different inhalers require different “breaths”—some need a quick, deep “huff,” while others need a slow, steady inhale. Always ask your pharmacist or respiratory therapist to observe your technique [21].

Common questions in this guide

How is the first COPD inhaler chosen?
Your clinician uses your symptoms and risk of flare-ups, summarized in the ABE grouping, to choose initial treatment. People with fewer symptoms and lower risk may start with one long-acting airway-opening medicine, while people with more symptoms or higher risk may start with two. Before increasing treatment, the care team should check adherence, inhaler technique, and other possible diagnoses.
When might I need an inhaled steroid for COPD?
An inhaled corticosteroid may be considered if you have repeated flare-ups despite two long-acting bronchodilators or if you also have asthma. A blood eosinophil count helps estimate whether it is likely to help; a count of 300 cells per microliter or more suggests greater potential benefit but is not an absolute cutoff. Unneeded use can increase the risk of pneumonia, oral thrush, and a hoarse voice.
Which vaccines are recommended for people with COPD?
People with COPD should receive an annual influenza vaccine and may need pneumococcal, RSV, COVID-19, Tdap, and shingles vaccines. The exact schedule depends on age, immune status, country, and previous doses, so review your record with a clinician.
Can pulmonary rehabilitation help me manage COPD?
Pulmonary rehabilitation is a supervised program combining exercise, education, and support. It does not repair the lungs, but it can train the heart and muscles to use oxygen more efficiently, improving walking ability and daily quality of life. After a COPD hospitalization for a flare-up, starting within about three weeks of discharge may help lower readmission risk.
How can I tell if I am using my COPD inhaler correctly?
Use maintenance inhalers every day as prescribed, even when breathing feels normal. Each device has its own breathing method, so ask a pharmacist or respiratory therapist to watch you use it; some devices may work better with a spacer. Correct technique helps more medicine reach the lungs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific 'letter' group am I in (A, B, or E), and how does that decide whether I start with one or two long-acting bronchodilators?
  2. 2.What is my latest blood eosinophil count, and is it in a range to justify adding an inhaled corticosteroid to my regimen?
  3. 3.Based on my age and previous vaccinations, which specific pneumococcal and RSV vaccines do I need right now?
  4. 4.Can you refer me to a pulmonary rehabilitation program? If I’ve had a recent flare-up, how soon can I start?
  5. 5.Can you watch me use my inhaler to make sure my technique is correct, or would a spacer help me get more medication into my lungs?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Long-acting muscarinic antagonist and long-acting β2-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review.

    Buhl R, Miravitlles M, Anzueto A, Brunton S

    Therapeutic advances in respiratory disease 2024; (18()):17534666241279115 doi:10.1177/17534666241279115.

    PMID: 39352722
  2. 2

    Stepwise management of COPD: What is next after bronchodilation?

    Miravitlles M, Matsunaga K, Dreher M

    Therapeutic advances in respiratory disease 2023; (17()):17534666231208630 doi:10.1177/17534666231208630.

    PMID: 37936381
  3. 3

    COPD: A Comprehensive Overview of a Prevalent Disease.

    Li ZP

    JAAPA : official journal of the American Academy of Physician Assistants 2026; (39(7)):20-27 doi:10.1097/01.JAA.0000000000000377.

    PMID: 42332389
  4. 4

    Vaccination in Chronic Obstructive Pulmonary Disease.

    Kwok WC, Wong JC, Cheung A, Tam TC

    Vaccines 2025; (13(3)) doi:10.3390/vaccines13030218.

    PMID: 40266071
  5. 5

    Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.

    Walters JA, Tang JN, Poole P, Wood-Baker R

    The Cochrane database of systematic reviews 2017; (1()):CD001390 doi:10.1002/14651858.CD001390.pub4.

    PMID: 28116747
  6. 6

    Role of Vaccination in the Prevention of ECOPD.

    Sartori F, Crisafulli E, Cariqueo M, et al.

    Seminars in respiratory and critical care medicine 2026; (47(3)):323-333 doi:10.1055/a-2837-8778.

    PMID: 41871621
  7. 7

    The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus.

    Simon S, Joean O, Welte T, Rademacher J

    European respiratory review : an official journal of the European Respiratory Society 2023; (32(169)) doi:10.1183/16000617.0034-2023.

    PMID: 37673427
  8. 8

    The effect of recombinant zoster vaccine on patients with chronic obstructive pulmonary diseases: A multi-institutional propensity score-matched cohort study.

    Tsai YW, Zhang B, Wu JY, et al.

    Journal of medical virology 2024; (96(9)):e29911 doi:10.1002/jmv.29911.

    PMID: 39233510
  9. 9

    Influenza vaccine for chronic obstructive pulmonary disease (COPD).

    Kopsaftis Z, Wood-Baker R, Poole P

    The Cochrane database of systematic reviews 2018; (6()):CD002733 doi:10.1002/14651858.CD002733.pub3.

    PMID: 29943802
  10. 10

    Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.

    Brunton SA, Hogarth DK

    Postgraduate medicine 2023; (135(8)):784-802 doi:10.1080/00325481.2023.2284650.

    PMID: 38032494
  11. 11

    LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.

    Miravitlles M, Kawayama T, Dreher M

    Journal of clinical medicine 2022; (11(22)) doi:10.3390/jcm11226623.

    PMID: 36431099
  12. 12

    Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.

    Melani AS, Croce S, Fabbri G, et al.

    Biomolecules 2024; (14(2)) doi:10.3390/biom14020195.

    PMID: 38397432
  13. 13

    Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.

    Pascoe S, Barnes N, Brusselle G, et al.

    The Lancet. Respiratory medicine 2019; (7(9)):745-756 doi:10.1016/S2213-2600(19)30190-0.

    PMID: 31281061
  14. 14

    Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.

    Suissa S, Dell'Aniello S, Ernst P

    The Lancet. Respiratory medicine 2018; (6(11)):855-862 doi:10.1016/S2213-2600(18)30368-0.

    PMID: 30343028
  15. 15

    Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks.

    Mkorombindo T, Dransfield MT

    Clinics in chest medicine 2020; (41(3)):475-484 doi:10.1016/j.ccm.2020.05.006.

    PMID: 32800200
  16. 16

    Pulmonary rehabilitation in patients with an acute exacerbation of chronic obstructive pulmonary disease.

    Jones SE, Barker RE, Nolan CM, et al.

    Journal of thoracic disease 2018; (10(Suppl 12)):S1390-S1399 doi:10.21037/jtd.2018.03.18.

    PMID: 29928521
  17. 17

    Pulmonary Rehabilitation Programmes Within Three Days of Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

    Zhang D, Zhang H, Li X, et al.

    International journal of chronic obstructive pulmonary disease 2021; (16()):3525-3538 doi:10.2147/COPD.S338074.

    PMID: 34992360
  18. 18

    Outcome of pulmonary rehabilitation in patients after acute exacerbation of chronic obstructive pulmonary disease.

    Deepak TH, Mohapatra PR, Janmeja AK, et al.

    The Indian journal of chest diseases & allied sciences 2014; (56(1)):7-12.

    PMID: 24930201
  19. 19

    Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

    Wedzicha JA, Miravitlles M, Hurst JR, et al.

    The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.00791-2016.

    PMID: 28298398
  20. 20

    The timing of the commencement of pulmonary rehabilitation in hospitalized patients with acute exacerbation of COPD: a systematic review and network meta-analysis.

    Jia P, Zhang H, Li Y, et al.

    BMC medicine 2026; (24(1)).

    PMID: 41840577
  21. 21

    [COPD - what has changed in GOLD 2023 and is relevant for clinical practice?]

    Klemmer A, Alter P, Vogelmeier CF

    Deutsche medizinische Wochenschrift (1946) 2023; (148(12)):780-787 doi:10.1055/a-1997-1375.

    PMID: 37257481

This page is for informational purposes only and does not constitute medical advice. Ask your clinician, pharmacist, or respiratory therapist to tailor COPD inhalers, vaccines, and rehabilitation to your needs.

Get notified when new evidence is published on chronic obstructive pulmonary disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.